Given the significance of GR activity in ENZ-resistant PCa cells [1, 7] and the positive association between EP300 chromatin occupancy in lung cancer cells and GR binding [30], EP300/CREBBP inhibitors could potentially counteract the GR-mediated replacement of AR signaling. The gene discussed is NR3C1; the disease is posterior cortical atrophy.